Strongbridge Biopharma Plc Revenue Growth Rates (SBBP), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Industry, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Strongbridge Biopharma plc  (NASDAQ: SBBP)
 

SBBP's Revenue Growth by Quarter and Year

Strongbridge Biopharma Plc's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

SBBP Revenue (in millions $) FY 2021 FY 2020 FY 2019 FY 2018
4th Quarter December -
3rd Quarter September -
2nd Quarter June 10.04
1st Quarter March 8.38
FY 18.42





SBBP Revenue second quarter 2021 Y/Y Growth Comment
Strongbridge Biopharma plc reported Revenue improvement of 29.41% year on year in the second quarter 2021, to $ 10.04 millions, this is lower than Strongbridge Biopharma Plc's recent average Revenue rise of 50.2%.

Looking into second quarter 2021 results within Major Pharmaceutical Preparations industry 119 other companies have achieved higher Revenue growth. While Strongbridge Biopharma Plc' s Revenue rise of 29.41% ranks overall at the positon no. 2075 in the second quarter 2021.


SBBP Revenue ( Y/Y Growth %) 2021
 2020 2019 2018
4th Quarter December - 46.7 % 24.39 % 51.34 %
3rd Quarter September - 42.08 % 6.17 % 111.46 %
2nd Quarter June 29.41 % 27.63 % 41.4 % 181.05 %
1st Quarter March 25.64 % 53.69 % 12.14 % -
FY   - 41.55 % 20.41 % -

Financial Statements
Strongbridge Biopharma Plc's second quarter 2021 Revenue $ 10.04 millions SBBP's Income Statement
Strongbridge Biopharma Plc's second quarter 2020 Revenue $ 7.76 millions Quarterly SBBP's Income Statement


SBBP Revenue (Quarter on Quarter Growth %)

 2021
 2020 2019 2018
4th Quarter December - 1.98 % -1.23 % -15.7 %
3rd Quarter September - 3.99 % -6.58 % 24.42 %
2nd Quarter June 19.83 % 16.34 % 40.09 % 11.11 %
1st Quarter March 1.82 % 18.89 % -3.77 % 29.87 %
FY (Year on Year)   - 41.55 % 20.41 % -


Back to SBBP Growth rate Comparisons >> Back to SBBP Growth rate Comparisons >>


Revenue second quarter 2021 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #120
Healthcare Sector #387
Overall #2075

Revenue Y/Y Growth Statistics
High Average Low
180.97 % 50.2 % 6.3 %
(Jun 30 2018)   (Sep 30 2019)
Revenue second quarter 2021 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #120
Healthcare Sector #387
Overall #2075
Revenue Y/Y Growth Statistics
High Average Low
180.97 % 50.2 % 6.3 %
(Jun 30 2018)   (Sep 30 2019)

Revenue by Quarter for the Fiscal Years 2018, 2019, 2020, 2021

Strongbridge Biopharma Plc's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
65.66 % 14.02 % -15.58 %
(Sep 30 2017)  


SBBP's II. Quarter Q/Q Revenue Comment
Strongbridge Biopharma plc achieved in the II. Quarter 2021 above company average sequential Revenue jump of 19.83%, to $ 10.04 millions, from $8.38 millions in the first quarter.
SBBP is undergoing a remarkable growth, with claiming higher then normal increase, and additionally increasing rate.

Within Major Pharmaceutical Preparations industry 97 other companies have achieved higher Revenue quarter on quarter growth. While Strongbridge Biopharma Plc's Revenue growth quarter on quarter, overall rank is 949.


Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #98
Healthcare Sector #186
Overall #949
Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #98
Healthcare Sector #186
Overall #949
Revenue Q/Q Growth Statistics
High Average Low
65.66 % 14.02 % -15.58 %
(Sep 30 2017)  


SBBP's II. Quarter Q/Q Revenue Comment
Strongbridge Biopharma plc achieved in the II. Quarter 2021 above company average sequential Revenue jump of 19.83%, to $ 10.04 millions, from $8.38 millions in the first quarter.
SBBP is undergoing a remarkable growth, with claiming higher then normal increase, and additionally increasing rate.

Within Major Pharmaceutical Preparations industry 97 other companies have achieved higher Revenue quarter on quarter growth. While Strongbridge Biopharma Plc's Revenue growth quarter on quarter, overall rank is 949.


Strongbridge Biopharma Plc's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Jun 30 2021)		 12 Months Ending
(Mar 31 2021)		 12 Months Ending
(Dec 31 2020)		 12 Months Ending
(Sep 30 2020)		 12 Months Ending
(Jun 30 2020)
Cumulative Revenue 12 Months Ending $ 34.72 $ 32.44 $ 30.73 $ 28.11 $ 25.72
Y / Y Revenue Growth (TTM) 34.98 % 34.92 % 41.54 % 36.33 % 26.83 %
Year on Year Revenue Growth Overall Ranking # 929 # 442 # 171 # 206 # 515
Seqeuential Revenue Change (TTM) 7.03 % 5.56 % 9.32 % 9.28 % 6.99 %
Seq. Revenue Growth (TTM) Overall Ranking # 2215 # 1100 # 397 # 523 # 1861


Cumulative Revenue growth Comment
Although Strongbridge Biopharma Plc's Annual Revenue growth year on year were below company's average 36.77% , Revenue announced in the Jun 30 2021 period, show improvement in Revenue trend, to cumulative trailing twelve month growth of 34.98% year on year, from 34.92% in Mar 31 2021.

In the Healthcare sector 202 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 442 to 929.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 123
Healthcare Sector # 203
Overall # 929

Revenue TTM Y/Y Growth Statistics
High Average Low
69.48 %
 36.77 %
20.44 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 123
Sector # 360
S&P 500 # 2215
Cumulative Revenue growth Comment
Although Strongbridge Biopharma Plc's Annual Revenue growth year on year were below company's average 36.77% , Revenue announced in the Jun 30 2021 period, show improvement in Revenue trend, to cumulative trailing twelve month growth of 34.98% year on year, from 34.92% in Mar 31 2021.

In the Healthcare sector 202 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 442 to 929.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 123
Healthcare Sector # 203
Overall # 929

Revenue TTM Y/Y Growth Statistics
High Average Low
69.48 %
36.77 %
20.44 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 123
Sector # 360
S&P 500 # 2215




Other Revenue Growth
Major Pharmaceutical Preparations Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
SBBP's Revenue Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue jump for the quarter ending Jun 30 2021 within Healthcare SectorY/Y Change %Revenue for the quarter ending Jun 30 2021
U S Physical Therapy Inc51.36%$ 51.362 millions
Global Blood Therapeutics Inc.50.96%$ 50.963 millions
Sage Therapeutics Inc 50.87%$ 50.872 millions
Dynatronics Corporation50.78%$ 50.780 millions
Integra Lifesciences Holdings Corp50.77%$ 50.771 millions
Aerie Pharmaceuticals Inc 50.75%$ 50.751 millions
Luna Innovations Inc50.39%$ 50.393 millions
Sorrento Therapeutics Inc 50.01%$ 50.006 millions
Nanostring Technologies Inc 49.81%$ 49.810 millions
Encision Inc 49.04%$ 49.042 millions
Emmaus Life Sciences Inc 48.83%$ 48.830 millions
Edwards Lifesciences Corporation48.76%$ 48.757 millions
Electromedical Technologies Inc 48.39%$ 48.392 millions
Bio techne Corp47.31%$ 47.314 millions
Healthlynked Corp47.28%$ 47.276 millions
Opko Health Inc 46.88%$ 46.878 millions
Neuronetics Inc 45.81%$ 45.806 millions
Tactile Systems Technology Inc 45.39%$ 45.387 millions
Inotiv Inc 45.21%$ 45.208 millions
Livanova Plc45.16%$ 45.156 millions
Surgery Partners Inc 45.00%$ 44.996 millions
Nuvasive Inc44.80%$ 44.799 millions
Steris Plc44.77%$ 44.771 millions
Iradimed Corporation44.38%$ 44.384 millions
Eargo Inc 43.73%$ 43.728 millions
Nephros Inc 43.69%$ 43.691 millions
Misonix Inc 43.55%$ 43.549 millions
Utah Medical Products Inc43.44%$ 43.439 millions
Procyon Corporation43.16%$ 43.162 millions
Cerus Corporation43.07%$ 43.074 millions


About Strongbridge Biopharma Plc Revenue Growth Rates (SBBP), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: the company’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.